Lite Strategy, formerly MEI Pharma and listed on Nasdaq, reported fiscal 2026 results for the year ended June 30 after adopting Litecoin as its primary reserve asset in August last year. The company said it had invested $100 million to purchase more than 900,000 LTC in total, with holdings of 832,716 LTC worth $57.22 million at June 30, representing more than 1% of all Litecoin mined to date. By Sept. 22, Lite Strategy had repurchased 6.4 million shares, or about 17% of shares outstanding, while its covered-call program had generated approximately $930,000 in option premium income. The company said it plans to increase LTC holdings per share through further buybacks and additional yield-generation strategies. Existing fiscal 2026 disclosures included $5.7 million in cash and cash equivalents, $34.9 million in digital assets available for unrestricted use or pledged as collateral, $42.7 million in total assets and no debt, as well as a $1 million investment in LitVM, a Litecoin Layer 2 project.